The therapeutic efficacy of STZ has been reported to be influenced by the status of both glucose transporter 2 (GLUT2) and O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells [15, 16]. This evidence concerns the gene MGMT and neoplasm.